Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Paediatric Respiratory Reviews

Volumn 24, Issue , 2017, Pages 32-34

  Aslam, Aisha ^a   Jahnke, Nikki ^a   Remmington, Tracey ^a   Southern, Kevin W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; OXADIAZOLE DERIVATIVE;

ARTICLE; CODON; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MUCOCILIARY CLEARANCE; PREMATURE TERMINATION CODON; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RISK FACTOR; GENETICS; MUTATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HUMANS; MUTATION; OXADIAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 85019899702     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2017.04.001     Document Type: Article

References (7)

1. Aslam, A.A., Higgins, C., Sinha, I.P., Southern, K.W., Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Cochrane Database of Systematic Reviews(1), 2017, 10.1002/14651858.CD012040.pub2 Art. No.: CD012040.
2. Welsh, M.J., Ramsey, B.W., Accurso, F., Cutting, G., Cystic fibrosis. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., (eds.) The Metabolic and Molecular Basis of Inherited Diseases, 8th Edition, 2001, McGraw-Hill, New York, 5121–5188.
3. Cystic Fibrosis Centre at the Hospital for Sick Children in Toronto, Canada. Cystic Fibrosis Mutation Database. www.genet.sickkids.on.ca/StatisticsPage.html (accessed 15.03.2015).
4. Kerem, E., Konstan, M.W., De Boeck, K., Accurso, F.J., Sermet-Gaudelus, I., Wilschanski, M., et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet. Respiratory Medicine 2:7 (2014), 539–547.
5. Higgins JPT, Altman DG, Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org/.
6. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org/.
7. ®) in patients with nonsense mutation cystic fibrosis. https://clinicaltrials.gov/ct2/show/NCT02139306.